bemcentinib   Click here for help

GtoPdb Ligand ID: 10478

Synonyms: BGB-324 | BGB324 | R-428 | R428
PDB Ligand
Compound class: Synthetic organic
Comment: Bemcentinib (BGB324, R428) is a potent, selective and orally active AXL receptor tyrosine kinase inhibitor that was discovered by Rigel as R428 [3] and which is being developed by BergenBio for anti-cancer potential [4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 97.26
Molecular weight 506.29
XLogP 5.05
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES Nc1nc(nn1c1nnc2c(c1)CCCc1c2cccc1)Nc1ccc2c(c1)CCC(CC2)N1CCCC1
Isomeric SMILES Nc1nc(nn1c1nnc2c(c1)CCCc1c2cccc1)Nc1ccc2c(c1)CC[C@H](CC2)N1CCCC1
InChI InChI=1S/C30H34N8/c31-29-33-30(32-24-13-10-20-11-14-25(15-12-22(20)18-24)37-16-3-4-17-37)36-38(29)27-19-23-8-5-7-21-6-1-2-9-26(21)28(23)35-34-27/h1-2,6,9-10,13,18-19,25H,3-5,7-8,11-12,14-17H2,(H3,31,32,33,36)/t25-/m0/s1
Bioactivity Comments
In preclinical tests bemcentinib blocked Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine production [3]. Bemcentinib inhibits infection by SARS-CoV-2 in cell assays with IC50 98-2100 nM depending on cell type [2].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
AXL receptor tyrosine kinase Hs Inhibitor Inhibition 7.8 pIC50 - 3
pIC50 7.8 (IC50 1.4x10-8 M) [3]